MedTrace Logo

A Study of Fostamatinib in Subjects With Impaired Hepatic (Liver) Function

NCT01222455 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2011-07-06

No results posted yet for this study

Summary

A study to evaluate the amount of fostamatinib in the blood in subjects with impaired hepatic (liver) function compared with healthy volunteers with normal liver function. The study will also evaluate safety and tolerability in subjects with hepatic impairment.

Conditions

  • Hepatic Impairment
  • Healthy Volunteers
  • Pharmacokinetics
  • Amount of R406 in Blood

Interventions

DRUG

Fostamatinib

Oral tablets, single dose

Sponsors & Collaborators

Principal Investigators

  • Thomas Marbury, MD · Orlando Clinical Research Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01222455 on ClinicalTrials.gov